The state of Illinois currently has 24 active clinical trials seeking participants for Dementia research studies. These trials are conducted in various cities, including Chicago, Peoria, Springfield and Urbana.
Study to Assess the Efficacy, Safety, and Tolerability of AVP-786 for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type
Recruiting
This study will be conducted to evaluate the efficacy, safety, and tolerability of AVP-786 (deudextromethorphan hydrobromide [d6-DM]/quinidine sulfate [Q]) compared to placebo for the treatment of agitation in participants with dementia of the Alzheimer's type.
Gender:
All
Ages:
Between 50 years and 90 years
Trial Updated:
03/26/2024
Locations: Clinical Research Site #840-030, Chicago, Illinois
Conditions: Agitation in Patients With Dementia of the Alzheimer's Type
Long Term, Extension Study of the Safety and Efficacy of AVP-786 for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type
Recruiting
This is an extension study of the Phase 3 Studies 15-AVP-786-301, 15-AVP-786-302, and 17-AVP-786-305, which also allows participants from the Phase 2 Study 12-AVR-131 to be included.
Gender:
All
Ages:
Between 50 years and 90 years
Trial Updated:
03/26/2024
Locations: Alexian Brothers Neurosciences Institute, Elk Grove Village, Illinois +1 locations
Conditions: Agitation in Patients With Dementia of the Alzheimer's Type
RewinD-LB - Clinical Study of Neflamapimod in Patients With Dementia With Lewy Bodies
Recruiting
The purpose of this study is to determine whether neflamapimod can improve learning skills, problem solving skills, and memory loss in people diagnosed with DLB. More specifically, improvement in verbal learning, memory, and attention, as well as cognitive and functional performance will be measured.
Gender:
All
Ages:
55 years and above
Trial Updated:
03/25/2024
Locations: Rush University Medical Center, Chicago, Illinois
Conditions: Dementia With Lewy Bodies
ARTFL LEFFTDS Longitudinal Frontotemporal Lobar Degeneration (ALLFTD)
Recruiting
ARTFL LEFFTDS Longitudinal Frontotemporal Lobar Degeneration (ALLFTD) represents the formalized integration of ARTFL (U54 NS092089; funded through 2019) and LEFFTDS (U01 AG045390; funded through 2019) as a single North American research consortium to study FTLD for 2019 and beyond.
Gender:
All
Ages:
18 years and above
Trial Updated:
03/12/2024
Locations: Northwestern University, Chicago, Illinois
Conditions: Frontotemporal Lobar Degeneration (FTLD), Progressive Supranuclear Palsy (PSP), Corticobasal Degeneration (CBD), Behavioral Variant Frontotemporal Dementia (bvFTD), Semantic Variant Primary Progressive Aphasia (svPPA), Nonfluent Variant Primary Progressive Aphasia (nfvPPA), FTD With Amyotrophic Lateral Sclerosis (FTD/ALS), Amyotrophic Lateral Sclerosis, Oligosymptomatic PSP (oPSP), C9orf72, GRN Related Frontotemporal Dementia, MAPT Gene Mutation, TBK1 Gene Mutation, Oligosymptomatic Progressive Supranuclear Palsy
Study to Evaluate the Safety, Tolerability and Efficacy of CT1812 in Subjects With Mild to Moderate Dementia With Lewy Bodies
Recruiting
Multi-center, randomized, double-blind, placebo-controlled, 6- month study in subjects with mild to moderate Dementia with Lewy Bodies.
Gender:
All
Ages:
Between 50 years and 85 years
Trial Updated:
03/12/2024
Locations: Rush University Medical Center Section of Parkinson Disease and Movement Disorder, Chicago, Illinois
Conditions: Dementia With Lewy Bodies
Alzheimer's Disease Neuroimaging Initiative 4
Recruiting
Since its launch in 2004, the overarching aim of the Alzheimer's Disease Neuroimaging Initiative (ADNI) Study has been to validate biomarkers for Alzheimer's disease (AD) clinical trials. ADNI4 continues the previously funded ADNI1, ADNI-GO, ADNI2, and ADNI3 studies that have combined public/private collaborations between academia and industry to determine the relationships between the clinical, cognitive, imaging, genetic and biochemical biomarker characteristics of the entire spectrum of AD.
Gender:
All
Ages:
Between 55 years and 90 years
Trial Updated:
03/12/2024
Locations: Rush University Memory Clinic, Chicago, Illinois
Conditions: Mild Cognitive Impairment, Alzheimer Disease, Dementia
Biomarkers for Vascular Contributions to Cognitive Impairment and Dementia Consortium
Recruiting
Biomarkers for Vascular Contributions to Cognitive Impairment and Dementia (MarkVCID) is an NIH-funded consortium dedicated to finding biomarkers involved in age-related thinking and memory problems. Alzheimer's disease and other dementias leave signatures on brain scans or in the blood called biomarkers. The MarkVCID study will measure a panel of candidate biomarkers in 1800 participants and watch them closely to see what they tell us about changes in brain function and risk of memory loss. Ag... Read More
Gender:
All
Ages:
Between 60 years and 90 years
Trial Updated:
02/27/2024
Locations: Rush University Medical Center & Illinois Institute of Technology, Chicago, Illinois
Conditions: Cognitive Impairment, Dementia
Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation (DIAN-TU)
Recruiting
To assess the safety, tolerability, biomarker, cognitive, and clinical efficacy of investigational products in participants with an Alzheimer's disease-causing mutation by determining if treatment with the study drug improves disease-related biomarkers and slows the rate of progression of cognitive or clinical impairment.
Gender:
All
Ages:
Between 18 years and 80 years
Trial Updated:
02/20/2024
Locations: Advocate Lutheran General Hospital, Park Ridge, Illinois
Conditions: Alzheimers Disease, Dementia, Alzheimers Disease, Familial
A Study to Evaluate the Effects of SAGE-718 in Participants With Mild Cognitive Impairment or Mild Dementia Due to Alzheimer's Disease (AD)
Recruiting
The primary purpose of this study is to evaluate the effect of SAGE-718 on cognitive performance in participants with Alzheimer's Disease.
Gender:
All
Ages:
Between 50 years and 80 years
Trial Updated:
02/15/2024
Locations: Sage Investigational Site, Chicago, Illinois
Conditions: Mild Cognitive Impairment, Mild Dementia, Alzheimer's Disease
Patient-Centered Dementia Care Practice Coaching Intervention
Recruiting
The goal of this clinical trial is to compare staff outcomes in long-term care communities who participate in the intervention versus those who do not. The main questions it aims to answer are: 1. Is employee satisfaction impacted by the intervention and 2. Is dementia care confidence impacted by the intervention. Participants will include monthly coaching visits for the intervention group and completion of surveys pre, immediately post and three-months post. Researchers will compare the interve... Read More
Gender:
All
Ages:
Between 18 years and 100 years
Trial Updated:
02/12/2024
Locations: Alzheimer's Association, Chicago, Illinois
Conditions: Dementia, Alzheimer Disease
Primary Care Detection of Cognitive Impairment Leveraging Health & Consumer Technologies in Underserved Communities: The MyCog Trial
Recruiting
Our study intends to offer 'real world' evidence of a viable, sustainable means to mobilize primary care via a comprehensive strategy for detecting cognitive impairment and dementias, advancing next steps for referral, and participating in the care planning and management of affected patients and caregivers. We will conduct a clinic-randomized, pragmatic trial testing the effectiveness and fidelity of our NIH Toolbox-derived paradigm to improve early detection and management of cognitive impairm... Read More
Gender:
All
Ages:
45 years and above
Trial Updated:
02/06/2024
Locations: Oak Street Health, Chicago, Illinois
Conditions: Dementia, Cognitive Impairment, Cognitive Decline, Alzheimer Disease
A Pivotal Study of Sensory Stimulation in Alzheimer's Disease (Hope Study, CA-0011)
Recruiting
This is a randomized, double-blind, sham-controlled, adaptive-design pivotal study of sensory stimulation in subjects with mild to moderate Alzheimer's disease. Approximately 530 subjects will be randomized to 12 months of daily treatment with either Active or Sham Sensory Stimulation Systems. Efficacy will be measured using the Alzheimer's Disease Cooperative Study- Activities of Daily Living (ADCS-ADL) assessment and a combined statistical test (CST) of the ADCS-ADL and the Mini-Mental State E... Read More
Gender:
All
Ages:
Between 50 years and 90 years
Trial Updated:
01/20/2024
Locations: Great Lakes Clinical Trials- Flourish Research- Chicago, Chicago, Illinois +1 locations
Conditions: Alzheimer Disease, Alzheimer Disease 1, Alzheimer Disease 2, Alzheimer Disease 3, Alzheimer Disease, Early Onset, Alzheimer Disease, Late Onset, Alzheimer Disease 9, Alzheimer Disease 4, Alzheimer Disease 7, Alzheimer Disease 17, Alzheimer's Dementia Late Onset, Alzheimer Disease 5, Alzheimer Disease 6, Alzheimer Disease 8, Alzheimer Disease 10, Alzheimer Disease 11, Alzheimer Disease 12, Alzheimer Disease 13, Alzheimer Disease 14, Alzheimer Disease 15, Alzheimer Disease 16, Alzheimer Disease 18, Alzheimer Disease 19, Dementia, Dementia Alzheimers, Dementia, Mild, Dementia of Alzheimer Type, Dementia Moderate, Dementia Senile, Mild Cognitive Impairment, Mild Dementia, MCI, Cognitive Impairment, Cognitive Decline, Cognitive Impairment, Mild